"A late-stage trial testing Bristol-Myers Squibb Co's cancer immunotherapy nivolumab in advanced melanoma patients was halted early after it was determined that the drug was likely to prolong survival, the company said on Tuesday..."
"The 418-patient Phase III study, called CheckMate -066, was testing nivolumab as an initial, or first line, therapy for patients with advanced melanoma, the deadliest form of skin cancer."
Editor's note: In a clinical trial with volunteer melanoma patients, researchers have been testing a new drug called nivolumab to see if it is a good first treatment for people with advanced melanoma. Nivolumab is an immunotherapy, meaning that it boosts a patient's own immune system to fight cancer. In the clinical trial, some of the patients were being treated with nivolumab, and some with a standard chemotherapy drug called dacarbazine. Nivolumab showed so much better results than dacarbazine that the trial was ended early, and the patients who had been taking dacarbazine were switched to nivolumab.